LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.58 -2.98

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.54

Max

3.58

Pagrindiniai rodikliai
By Trading Economics
Pajamos	8.3M -18M
Pardavimai	9.6M 10M
P/E Sektoriaus vid.	22.5 50.102
Pelnas, tenkantis vienai akcijai	-0.1
Pelno marža	-177.89
Darbuotojai	69
EBITDA	8M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+231.54% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-107M 803M
Ankstesnė atidarymo kaina	6.56
Ankstesnė uždarymo kaina	3.58

Naujienos nuotaikos

By Acuity

50%

161 / 344 reitingas Healthcare

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-29 23:08; UTC

Įsigijimai, susijungimai, perėmimai

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026-05-29 23:06; UTC

Įsigijimai, susijungimai, perėmimai

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026-05-29 20:53; UTC

Uždarbis

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026-05-29 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 20:33; UTC

Rinkos pokalbiai

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026-05-29 20:11; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 19:47; UTC

Uždarbis

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026-05-29 19:36; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-29 19:34; UTC

Rinkos pokalbiai

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026-05-29 19:22; UTC

Rinkos pokalbiai

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026-05-29 19:05; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026-05-29 18:19; UTC

Rinkos pokalbiai

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026-05-29 18:12; UTC

Įsigijimai, susijungimai, perėmimai

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026-05-29 18:11; UTC

Rinkos pokalbiai

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026-05-29 18:10; UTC

Rinkos pokalbiai

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026-05-29 17:55; UTC

Uždarbis

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026-05-29 17:55; UTC

Rinkos pokalbiai

NEAR Protocol Nearly Doubles in May -- Market Talk

2026-05-29 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026-05-29 17:00; UTC

Uždarbis

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026-05-29 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-29 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-05-29 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-29 16:02; UTC

Rinkos pokalbiai

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-29 15:55; UTC

Rinkos pokalbiai

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026-05-29 15:50; UTC

Įsigijimai, susijungimai, perėmimai

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026-05-29 15:50; UTC

Įsigijimai, susijungimai, perėmimai

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026-05-29 15:40; UTC

Rinkos pokalbiai

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026-05-29 15:20; UTC

Rinkos pokalbiai

Canada's Economy Not Looking All That Bright -- Market Talk

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

231.54% į viršų

12 mėnesių prognozė

Vidutinis 12.3 USD 231.54%

Aukščiausias 16 USD

Žemiausias 6 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

161 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.